0
0

Protecting Cures Act of 2020

2/8/2022, 11:17 PM

Congressional Summary of HR 6417

Protecting Cures Act of 2020

This bill prohibits the Department of Health and Human Services from withholding funding, because of ethical considerations, for research activities that use human fetal tissue, provided that the research activities have been recommended for approval by an institutional review board and otherwise comply with existing laws concerning human fetal tissue. The bill also establishes that this research is not unethical by deeming the 1988 report of the Human Fetal Tissue Transplantation Research Panel as meeting relevant statutory requirements with respect to approving the ethical status of such research.

Current Status of Bill HR 6417

Bill HR 6417 is currently in the status of Bill Introduced since March 31, 2020. Bill HR 6417 was introduced during Congress 116 and was introduced to the House on March 31, 2020.  Bill HR 6417's most recent activity was Referred to the House Committee on Energy and Commerce. as of March 31, 2020

Bipartisan Support of Bill HR 6417

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
22
Democrat Cosponsors
22
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 6417

Primary Policy Focus

Health

Potential Impact Areas

- Cell biology and embryology
- Medical ethics
- Medical research
- Organ and tissue donation and transplantation
- Research administration and funding

Alternate Title(s) of Bill HR 6417

Protecting Cures Act of 2020
To prohibit the Secretary of Health and Human Services from withholding funds for certain research using human fetal tissue, and for other purposes.
Protecting Cures Act of 2020

Comments